Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources

Stock MarketsSep 07, 2016 21:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources

By Carl O'Donnell and Arno Schuetze

(Reuters) - GW Pharmaceuticals Plc (L:GWP), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

The move shows how the Cambridge, England-based company is emerging as a coveted target for larger pharmaceutical companies thanks to its key drug, Epidolex, which uses cannabis-based compounds to treat epilepsy.

GW has hired investment bank Morgan Stanley (N:MS) to help handle the overtures, the people said this week. The company is not currently interested in exploring a sale, and there is no certainty that any deal will occur, the people added.

The identity of the potential suitors could not be established. The sources asked not to be identified because the deliberations are confidential.

GW declined to comment. Morgan Stanley did not respond to a request for comment.

GW shares ended trading in London up 0.6 percent at 526.50 pence (70 U.S. cents), giving the company a market capitalisation of 1.6 billion pounds ($2.1 billion). American depositary receipts of the company jumped as much as 22 percent in New York following the Reuters report.

GW's move is the latest sign that dealmaking in the biotechnology sector is picking up. Last month, Pfizer Inc (N:PFE) clinched a $14 billion acquisition of U.S. cancer drug company Medivation Inc (O:MDVN).

Major players in the market for central nervous system treatments, including Allergan Plc (N:AGN) and Biogen Inc (O:BIIB), are searching for deals to build out their commercial presence and research and development pipelines.

Logical buyers for GW would include the companies that have partnered with it to distribute its marketed drug, Sativex, a nasal spray for multiple sclerosis that is also based on marijuana, one of the people said.

GW's current partners include Novartis AG (S:NOVN), Bayer AG (DE:BAYGn) and Almirall SA (MC:ALM), among others.

Epidolex is in late-stage clinical trials and could receive approval from the U.S. Food and Drug Administration as soon as next year. It could eventually produce annual sales in excess of $800 million, according analysts at investment bank Cowen & Co.

The drug's success is especially important to GW because of the tepid performance of Sativex, which has been marketed since 2010.

Sativex was never approved in the United States, and only produced $2 million in sales in the latest financial quarter.

GW Pharma is also exploring early-stage treatments for other illnesses, including diabetes and schizophrenia.

Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources
 

Related Articles

Air France-KLM launches 2.3 billion euro share sale
Air France-KLM launches 2.3 billion euro share sale By Reuters - May 24, 2022

By Tim Hepher PARIS (Reuters) -Air France-KLM on Tuesday launched a 2.26-billion-euro ($2.41 billion) share sale to shore up its balance sheet and repay some French state aid as...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email